ARTIVION INC Reports Q2 FY2023 Earnings Results for Period Ending June 30 2023

August 22, 2023

🌥️Earnings Overview

On August 3 2023, ARTIVION INC ($NYSE:AORT) announced their financial results for the second quarter of FY2023, ending June 30 2023. The company reported total revenue of USD 89.2 million, a year-over-year growth of 11.1%. Net income was -3.4 million, an improvement over the previous year’s figure of -4.3 million.

Stock Price

ARTIVION INC, a leader in the telecommunication and information technology industry, released its Q2 FY2023 earnings results on Thursday for the period ending June 30 of 2023. The company’s stock opened at $17.0 and closed at $16.8, representing a decrease of 1.7% from the previous closing price of 17.1. Overall, the results from ARTIVION INC’s Q2 FY2023 earnings report are promising, with the company’s net income increasing year-over-year and their expenses being reduced. Despite a slight decrease in stock price, investors can remain optimistic about ARTIVION INC’s performance going forward. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Artivion Inc. More…

    Total Revenues Net Income Net Margin
    328.72 -28.4 -11.3%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Artivion Inc. More…

    Operations Investing Financing
    4.51 -1.49 2.8
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Artivion Inc. More…

    Total Assets Total Liabilities Book Value Per Share
    777.86 495.35 6.91
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Artivion Inc are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    8.4% -28.6% 0.5%
    FCF Margin ROE ROA
    -1.9% 0.4% 0.1%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    We have detected 3 risk warnings in the income sheet, balance sheet and cash flow statement. With our analysis, investors can understand the risks associated with investing in these companies. GoodWhale’s Risk Rating system flags companies with financial or business problems that could potentially lead to a poor performance of their investments. We have noticed some irregularities in ARTIVION INC‘s income sheet, balance sheet and cash flow statement. This includes changes in receivables, inventory, liabilities, and cash flow which all indicate potential risks. We invite investors to register with us to receive more detailed information about ARTIVION INC and other companies like it that we have analyzed. With this information, investors can make informed decisions about their investments. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company has a strong market presence in Europe and North America. Artivion Inc competes with BICO Group AB, IVF Hartmann Holding AG, and Bioventus Inc. in the global IVF market.

    – BICO Group AB ($OTCPK:CLLKF)

    BICO Group AB is a Swedish company that provides healthcare and hygiene products. The company has a market cap of 215.89M as of 2022 and a Return on Equity of 0.14%. BICO Group AB’s products include medical gloves, face masks, and disinfectants. The company’s products are used in hospitals, clinics, and by consumers.

    – IVF hartmann Holding AG ($LTS:0QQM)

    As of 2022, hartmann Holding AG has a market cap of 268.8M and a Return on Equity of 4.11%. The company is engaged in the production of medical and hygiene products.

    – Bioventus Inc ($NASDAQ:BVS)

    Bioventus Inc is a medical device company that focuses on the development and commercialization of products for the orthopedic market. The company has a market cap of 423.63M as of 2022 and a Return on Equity of -5.08%. Bioventus was founded in 2006 and is headquartered in Durham, NC.


    Investors are likely to be encouraged by the 11.1% increase in revenue reported by ARTIVION INC for the second quarter of FY2023. Despite a net income of -3.4 million, this figure is an improvement on the same quarter of the previous year, where net income was -4.3 million. The company’s financial performance indicates that it has successfully managed to drive growth despite the challenging market conditions. This could be an attractive opportunity for investors looking for a reliable return on their investments.

    Recent Posts

    Leave a Comment